CA2721980C - Selective high-affinity poly dentate ligands and methods of making such - Google Patents

Selective high-affinity poly dentate ligands and methods of making such Download PDF

Info

Publication number
CA2721980C
CA2721980C CA2721980A CA2721980A CA2721980C CA 2721980 C CA2721980 C CA 2721980C CA 2721980 A CA2721980 A CA 2721980A CA 2721980 A CA2721980 A CA 2721980A CA 2721980 C CA2721980 C CA 2721980C
Authority
CA
Canada
Prior art keywords
shal
ligand
linker
ligands
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2721980A
Other languages
English (en)
French (fr)
Other versions
CA2721980A1 (en
Inventor
Sally J. Denardo
Gerald L. Denardo
Rodney L. Balhorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Livermore National Security LLC
University of California San Diego UCSD
Original Assignee
Lawrence Livermore National Security LLC
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Livermore National Security LLC, University of California San Diego UCSD filed Critical Lawrence Livermore National Security LLC
Publication of CA2721980A1 publication Critical patent/CA2721980A1/en
Application granted granted Critical
Publication of CA2721980C publication Critical patent/CA2721980C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
CA2721980A 2008-04-21 2009-04-21 Selective high-affinity poly dentate ligands and methods of making such Active CA2721980C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4671208P 2008-04-21 2008-04-21
US61/046,712 2008-04-21
PCT/US2009/041276 WO2009132020A2 (en) 2008-04-21 2009-04-21 Selective high-affinity polydentate ligands and methods of making such

Publications (2)

Publication Number Publication Date
CA2721980A1 CA2721980A1 (en) 2009-10-29
CA2721980C true CA2721980C (en) 2017-01-03

Family

ID=41217391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721980A Active CA2721980C (en) 2008-04-21 2009-04-21 Selective high-affinity poly dentate ligands and methods of making such

Country Status (8)

Country Link
US (5) US9884070B2 (enExample)
EP (1) EP2268654B1 (enExample)
JP (2) JP5623384B2 (enExample)
CN (1) CN102083850B (enExample)
AU (1) AU2009239491B2 (enExample)
CA (1) CA2721980C (enExample)
ES (1) ES2613844T3 (enExample)
WO (1) WO2009132020A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762984A (zh) 2009-11-05 2012-10-31 弗吉尼亚大学专利基金会 用于检测作为癌症生物标志的网蛋白-1的组合物和方法
KR101939710B1 (ko) * 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
JP6103832B2 (ja) * 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
JP6190534B2 (ja) 2013-08-22 2017-08-30 ソニー株式会社 水溶性蛍光染料又は有色染料及びその使用方法
WO2016011037A1 (en) * 2014-07-14 2016-01-21 Peg Biosciences, Inc. Polymeric enkephalin prodrugs
CN105985524A (zh) * 2015-02-10 2016-10-05 北京师范大学 针对特定靶标具备指纹识别特征的多肽复合物分子的构建方法
KR102676814B1 (ko) 2015-02-26 2024-06-21 소니그룹주식회사 접합 그룹을 포함하는 수용성 형광 또는 착색 염료
JP6982500B2 (ja) 2015-02-26 2021-12-17 ソニーグループ株式会社 フェニルエチニルナフタレン染料およびそれらの使用方法
US10865310B2 (en) 2015-05-11 2020-12-15 Sony Corporation Of America Ultra bright dimeric or polymeric dyes
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
CN105678112B (zh) * 2016-02-03 2018-08-03 中国农业科学院北京畜牧兽医研究所 一种计算机辅助筛选小分子化合物靶标适配体的实现方法
CN107580618A (zh) 2016-04-01 2018-01-12 索尼公司 超亮二聚或多聚染料
CN109415574B (zh) 2016-04-01 2021-05-28 索尼公司 具有刚性间隔基团的超亮二聚体或聚合物染料
JP7069033B2 (ja) 2016-04-06 2022-05-17 ソニーグループ株式会社 スペーシングリンカー基を有する超明色ダイマーまたはポリマー染料
WO2017197014A2 (en) 2016-05-10 2017-11-16 Sony Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
JP7527537B2 (ja) 2016-05-10 2024-08-05 ソニーグループ株式会社 ペプチド骨格を有する超明色ポリマー染料
AU2017264861B2 (en) 2016-05-11 2021-09-23 Sony Group Corporation Ultra bright dimeric or polymeric dyes
WO2017214165A1 (en) 2016-06-06 2017-12-14 Sony Corporation Ionic polymers comprising fluorescent or colored reporter groups
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
WO2018098384A1 (en) * 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
US10871459B2 (en) 2017-02-17 2020-12-22 The Regents Of The University Of California Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
EP3691689A1 (en) * 2017-10-05 2020-08-12 Sony Corporation Programmable dendritic drugs
KR102762143B1 (ko) * 2017-11-01 2025-02-07 애로우헤드 파마슈티컬스 인코포레이티드 인테그린 리간드 및 그의 용도
JP2021503450A (ja) 2017-11-16 2021-02-12 ソニー株式会社 プログラム可能なポリマー薬
JP7813098B2 (ja) 2018-01-12 2026-02-12 ソニーグループ株式会社 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
CN111565757A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的磷酸烷基聚合物
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
WO2019182766A1 (en) 2018-03-21 2019-09-26 Sony Corporation Polymeric tandem dyes with linker groups
WO2019195466A1 (en) * 2018-04-03 2019-10-10 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses therof
KR102854332B1 (ko) 2018-06-27 2025-09-03 소니그룹주식회사 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
CN109283842B (zh) * 2018-08-02 2022-01-07 哈尔滨工程大学 一种无人艇航迹跟踪智能学习控制方法
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
JP7816141B2 (ja) 2019-09-30 2026-02-18 ソニーグループ株式会社 ヌクレオチドプローブ
WO2021127583A1 (en) * 2019-12-20 2021-06-24 Shal Technologies, Inc. Selective high affinity ligand diagnostics and therapeutics
BR112022020332A2 (pt) * 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN115043898B (zh) * 2021-03-08 2024-12-31 迈克生物股份有限公司 生物素化抗原衍生物及相关试剂盒和用途
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
WO2023138755A1 (en) * 2022-01-18 2023-07-27 NEC Laboratories Europe GmbH Methods of vaccine design
WO2024059858A2 (en) * 2022-09-15 2024-03-21 Ligandal, Inc. Approaches to discovering, analyzing, and synthesizing compounds through automated in silico experimentation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
ATE210682T1 (de) 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
US6217871B1 (en) 1998-10-28 2001-04-17 The Regents Of The University Of California Antigenic epitopes with LYM-1 reactivity and uses thereof
GB0016361D0 (en) 2000-07-03 2000-08-23 Chiron Spa Structure-based HCV drug design
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US20040242851A1 (en) 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
ATE423571T1 (de) 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
AU2002335808B2 (en) 2001-10-15 2009-08-27 Ibc Pharmaceuticals Affinity enhancement agents
DE10256530A1 (de) * 2002-12-04 2004-06-24 Degussa Ag Verfahren zur Herstellung von wasserfreiem Alkalisulfid
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005077065A2 (en) * 2004-02-09 2005-08-25 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Also Published As

Publication number Publication date
US20210000843A1 (en) 2021-01-07
US20180008622A1 (en) 2018-01-11
WO2009132020A2 (en) 2009-10-29
EP2268654A4 (en) 2012-06-06
US10646502B2 (en) 2020-05-12
US20180008621A1 (en) 2018-01-11
JP2011518194A (ja) 2011-06-23
US10292992B2 (en) 2019-05-21
WO2009132020A3 (en) 2009-12-23
US9884070B2 (en) 2018-02-06
AU2009239491A1 (en) 2009-10-29
CN102083850A (zh) 2011-06-01
CN102083850B (zh) 2015-08-12
ES2613844T3 (es) 2017-05-26
AU2009239491B2 (en) 2014-07-17
US11285165B2 (en) 2022-03-29
EP2268654A2 (en) 2011-01-05
JP2014122234A (ja) 2014-07-03
JP5623384B2 (ja) 2014-11-12
CA2721980A1 (en) 2009-10-29
US10874678B2 (en) 2020-12-29
US20190262364A1 (en) 2019-08-29
US20110144065A1 (en) 2011-06-16
EP2268654B1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
US11285165B2 (en) Selective high-affinity polydentate ligands and methods of making such
US8536133B2 (en) Selective high-affinity polydentate ligands and methods of making such
JP7133611B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
KR101523705B1 (ko) Ｓｐａｒｃ 결합 ｓｃｆｖｓ
EP3702367A1 (en) Novel pd-l1 binding polypeptides for imaging
JP2007527391A (ja) 二重特異性抗体の多価キャリヤー
JP2002537362A (ja) ビオチン化ケモカイン抗体複合体
US20220144898A1 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US20210106677A1 (en) Vaccine development methodology based on an adhesion molecule
Wilbur et al. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
JPH09501147A (ja) モノアミンオキシダーゼを使用する免疫反応性試薬
JP2022514148A (ja) シンデカン－１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質
WO2025083185A1 (en) Reducing off-target accumulation of targeted pharmaceutical compounds
JP2023515633A (ja) 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140415

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241023